Target Name: LIPT1
NCBI ID: G51601
Review Report on LIPT1 Target / Biomarker Content of Review Report on LIPT1 Target / Biomarker
LIPT1
Other Name(s): lipoyltransferase 1 | LIPT1D | Lipoyl ligase | Lipoyltransferase 1, transcript variant 1 | lipoyl ligase | Lipoate biosynthesis protein | lipoate biosynthesis protein | LIPT1 variant 1 | LIPT_HUMAN | Lipoate-protein ligase | Lipoyltransferase 1, mitochondrial

LIPT1: A Potential Drug Target for Cardiovascular Disease, Diabetes and Cancer

Lipoyltransferase 1 (LIPT1) is a protein that is expressed in various tissues throughout the body, including muscle, heart, and brain. It plays a critical role in the transfer of phosphate groups from adenosine triphosphate (ATP) to lipids, which is a crucial step in the production of energy.

Recent studies have suggested that LIPT1 may be a potential drug target or biomarker for various diseases, including heart disease, diabetes, and cancer. In this article, we will explore the potential mechanisms by which LIPT1 may be involved in these diseases and discuss the potential clinical applications of targeting LIPT1.

1. Cardiovascular disease

Cardiovascular disease is a leading cause of death worldwide, and there is a significant need for new treatments that can effectively prevent or reverse the progression of this disease. LIPT1 has been shown to play a critical role in the regulation of cellular metabolism, including the production of ATP. By inhibiting LIPT1 function, researchers have found that they can reduce the production of ATP, which can lead to cellular dysfunction and death.

One potential mechanism by which LIPT1 may contribute to cardiovascular disease is by contributing to the regulation of cell signaling pathways that are involved in the development of plaque, a common cause of heart disease. LIPT1 has been shown to be involved in the production ofreactive oxygen species (ROS), which can contribute to the oxidation of lipids and the formation of plaque.

In addition, LIPT1 has also been shown to regulate the production of adenosine, a molecule that plays a critical role in the regulation of cellular signaling pathways and has been linked to the development of various cardiovascular diseases. By inhibiting LIPT1 function, researchers have found that they can reduce the production of adenosine, which can lead to the inhibition of signaling pathways that are involved in the development of cardiovascular disease.

1. Diabetes

Diabetes is a chronic metabolic disorder that is characterized by high levels of glucose in the blood. LIPT1 has been shown to play a critical role in the regulation of cellular metabolism, including the production of ATP. By inhibiting LIPT1 function, researchers have found that they can reduce the production of ATP, which can lead to cellular dysfunction and death.

In addition, LIPT1 has also been shown to contribute to the regulation of the production of glucose. Glucose is a critical source of energy for the body, and it is produced by the liver from the consumption of fatty acids. LIPT1 has been shown to be involved in the production of fatty acids, which are then used as a source of energy by the body.

1. Cancer

Cancer is a leading cause of death worldwide, and there is a significant need for new treatments that can effectively prevent or reverse the progression of this disease. LIPT1 has been shown to play a critical role in the regulation of cellular metabolism, including the production of ATP. By inhibiting LIPT1 function, researchers have found that they can reduce the production of ATP, which can lead to cellular dysfunction and death.

In addition, LIPT1 has also been shown to contribute to the regulation of the production of glucose. Glucose is a critical source of energy for the body, and it is produced by the liver from the consumption of fatty acids. LIPT1 has been shown to be involved in the production of fatty acids, which are then used as a source of energy by the body.

1. The potential clinical applications of targeting LIPT1

The potential clinical applications of targeting LIPT1 are vast and varied. One of the most promising potential applications of targeting LIPT1 is the treatment of cardiovascular disease. By inhibiting LIPT1 function, researchers have found that they can reduce the production of ATP, which can lead to cellular dysfunction and death

Protein Name: Lipoyltransferase 1

Functions: Catalyzes the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes

The "LIPT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIPT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LIPT2 | LIPT2-AS1 | LITAF | Liver Bile Transporters (LBAT) | LIX1 | LIX1-AS1 | LIX1L | LKAAEAR1 | LKB1-LIP1-SMAD4 complex | LL22NC03-63E9.3 | LLCFC1 | LLGL1 | LLGL2 | LLPH | LMAN1 | LMAN1L | LMAN2 | LMAN2L | LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207